Bio-Techne Corp
TECH65.850USD
+2.360+3.72%
Fechamento 11/25, 16:00（ET）Cotações atrasadas em 15 min
10.26BValor de mercado
131.57P/L TTM
Mais detalhes de Bio-Techne Corp Empresa
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Informações de Bio-Techne Corp
Código da empresaTECH
Nome da EmpresaBio-Techne Corp
Data de listagemFeb 09, 1989
CEOMr. Kim Kelderman
Número de funcionários3100
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 09
Endereço614 Mckinley Pl N E
CidadeMINNEAPOLIS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal55413
Telefone16123792956
Sitehttps://www.bio-techne.com/
Código da empresaTECH
Data de listagemFeb 09, 1989
CEOMr. Kim Kelderman
Executivos da empresa Bio-Techne Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+2.51%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-4.52%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+3.66%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+11.91%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+17.55%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+22.99%
Dr. Matthew F. Mcmanus
Dr. Matthew F. Mcmanus
President - Diagnostics and Spatial Biology
President - Diagnostics and Spatial Biology
4.74K
+169.49%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
4.38K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
3.78K
+76.56%
Mr. James T. (Jim) Hippel
Mr. James T. (Jim) Hippel
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+2.51%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-4.52%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+3.66%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+11.91%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+17.55%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+22.99%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Consumables
972.29M
79.72%
Instruments
112.09M
9.19%
Service
111.57M
9.15%
Royalty
23.69M
1.94%
Por RegiãoUSD
Nome
Receita
Proporção
United States
683.23M
56.02%
EMEA, excluding U.K
266.31M
21.83%
Greater China
100.46M
8.24%
APAC, excluding Greater China
77.26M
6.33%
United Kingdom
54.83M
4.50%
Rest of World
37.55M
3.08%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Consumables
972.29M
79.72%
Instruments
112.09M
9.19%
Service
111.57M
9.15%
Royalty
23.69M
1.94%
Distribuição de ações
Atualizado em: dom, 16 de nov
Atualizado em: dom, 16 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Outro
72.73%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Outro
72.73%
Tipos de investidores
Investidores
Proporção
Investment Advisor
57.86%
Investment Advisor/Hedge Fund
34.00%
Hedge Fund
8.05%
Bank and Trust
2.18%
Research Firm
1.96%
Pension Fund
1.33%
Sovereign Wealth Fund
1.24%
Individual Investor
0.28%
Insurance Company
0.24%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
1198
161.18M
103.53%
-7.34M
2025Q2
1209
165.25M
105.41%
-730.33K
2025Q1
1245
168.10M
107.22%
+1.54M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
2023Q2
1213
155.36M
98.68%
-4.04M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
18.40M
11.82%
-60.83K
-0.33%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.79M
5.65%
-512.26K
-5.50%
Jun 30, 2025
State Street Investment Management (US)
5.86M
3.76%
-671.30K
-10.28%
Jun 30, 2025
Atlanta Capital Management Company, L.L.C.
4.29M
2.76%
+573.23K
+15.41%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.06M
2.61%
-30.89K
-0.75%
Jun 30, 2025
Invesco Capital Management LLC
3.24M
2.08%
+274.96K
+9.28%
Jun 30, 2025
Neuberger Berman, LLC
2.50M
1.61%
-526.06K
-17.38%
Jun 30, 2025
T. Rowe Price Associates, Inc.
8.62M
5.53%
-2.53M
-22.68%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
Global X Genomics & Biotechnology ETF
3.95%
Invesco Biotechnology & Genome ETF
2.62%
Invesco S&P 500 Equal Weight Health Care ETF
1.79%
VanEck Biotech ETF
1.63%
Neuberger Berman Small-Mid Cap ETF
1.58%
Hilton Small-MidCap Opportunity ETF
1.55%
Thrivent Small-Mid Cap ESG ETF
1.44%
American Century Mid Cap Growth Impact ETF
1.39%
WisdomTree BioRevolution Fund
1.22%
iShares Health Innovation Active ETF
1.2%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção3.95%
Invesco Biotechnology & Genome ETF
Proporção2.62%
Invesco S&P 500 Equal Weight Health Care ETF
Proporção1.79%
VanEck Biotech ETF
Proporção1.63%
Neuberger Berman Small-Mid Cap ETF
Proporção1.58%
Hilton Small-MidCap Opportunity ETF
Proporção1.55%
Thrivent Small-Mid Cap ESG ETF
Proporção1.44%
American Century Mid Cap Growth Impact ETF
Proporção1.39%
WisdomTree BioRevolution Fund
Proporção1.22%
iShares Health Innovation Active ETF
Proporção1.2%
Dividendo
Um total de
250.90M
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Feb 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
May 03, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023
May 15, 2023
May 26, 2023
May 12, 2023
Feb 02, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023
Feb 13, 2023
Feb 27, 2023
Feb 10, 2023
Nov 01, 2022
TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Nov 28, 2022
Nov 10, 2022
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Nov 01, 2022
Split
1→4
Data
Tipo
Proporção
Nov 01, 2022
Split
1→4
Perguntas frequentes
Quem são os cinco principais acionistas de Bio-Techne Corp?
Os cinco principais acionistas de Bio-Techne Corp são:
The Vanguard Group, Inc. detém 18.40M Ações, representando 11.82% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 8.79M Ações, representando 5.65% do total de Ações.
State Street Investment Management (US) detém 5.86M Ações, representando 3.76% do total de Ações.
Atlanta Capital Management Company, L.L.C. detém 4.29M Ações, representando 2.76% do total de Ações.
Geode Capital Management, L.L.C. detém 4.06M Ações, representando 2.61% do total de Ações.
The Vanguard Group, Inc. detém 18.40M Ações, representando 11.82% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 8.79M Ações, representando 5.65% do total de Ações.
State Street Investment Management (US) detém 5.86M Ações, representando 3.76% do total de Ações.
Atlanta Capital Management Company, L.L.C. detém 4.29M Ações, representando 2.76% do total de Ações.
Geode Capital Management, L.L.C. detém 4.06M Ações, representando 2.61% do total de Ações.
Quais são os três principais tipos de acionistas de Bio-Techne Corp?
Os três principais tipos de acionistas da Bio-Techne Corp são:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Quantas instituições possuem ações da Bio-Techne Corp (TECH)?
Em 2025Q3, 1198 instituições possuíam ações da Bio-Techne Corp, com valor de mercado aproximado de 161.18M, representando 103.53% do total de ações. Em comparação com 2025Q2, a participação institucional aumentou em -1.88%.
Qual é a maior fonte de receita da Bio-Techne Corp?
Em FY2025, o segmento de negócios Consumables gerou a maior receita para Bio-Techne Corp, totalizando 972.29M e representando 79.72% da receita total.
